Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 368Neoplasms 324Neoplasm Metastasis 287Leukemia, Myeloid, Acute 279Breast Neoplasms 275Colorectal Neoplasms 233Melanoma 197Ovarian Neoplasms 189Recurrence 187Multiple Myeloma 177Prostatic Neoplasms 156Pancreatic Neoplasms 156Lung Neoplasms 156Squamous Cell Carcinoma of Head and Neck 148Glioblastoma 145Lymphoma, Non-Hodgkin 143Triple Negative Breast Neoplasms 118Myelodysplastic Syndromes 114Carcinoma, Renal Cell 111Stomach Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Glioma 105Advanced Solid Tumors 104Lymphoma 103Lymphoma, Large B-Cell, Diffuse 102Brain Neoplasms 102Lymphoma, B-Cell 98Carcinoma, Hepatocellular 94Endometrial Neoplasms 92Lymphoma, Follicular 90

Interventions

pembrolizumab 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Recurrence, Local × 1 year × Clear all
NCT06912087 2025-12-02

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

University of Chicago

Phase 1 Recruiting
36 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Data powered by HemOnc (CC BY 4.0) Colophon âš¡